Effectiveness of therapy with acotinamide hydrochloride and Trimebutine Maleateon gastro-oesophagial disease in systemic sclerosis
Phase 3
- Conditions
- systemic sclerosis
- Registration Number
- JPRN-UMIN000026859
- Lead Sponsor
- Third Department of Internal Medicine (Department of Rheumatology) Shimane University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) the patients who have taken proton pomp inhibitor or vonoprazan within 2 months. 2) the patients who have sensitivity against acotinamide hydrochloride or trimebutine maleateon
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method